BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics in 2023 and the drug's approval last September ended a decades-long drought in new-mechanism therapies for ...

Cobenfy’s launch is tracking against expectations, having surpassed 30,000 total scripts following an FDA approval in late September, according to Lenkowsky. However, a Leerink Partners analysis ...

The United States-based Karuna Foundation has awarded a USD 1 million grant to the Tarayana Foundation to support the construction of disaster-resilient homes for Bhutan’s most vulnerable communities.

With its 1,800 square-foot ISO 7 manufacturing facility, Nutcracker Therapeutics will significantly increase production capacity to more than 2,000 patient-specific therapeutics annually.

Otsuka tops Vera Therapeutics in kidney disease study showdown Both companies are racing to develop new treatments for IgA nephropathy Adobe By Adam Feuerstein June 6, 2025 Senior Writer, Biotech ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the ...

Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable safety results.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal ...